These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 9670036)

  • 1. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy.
    Morris L; Binley JM; Clas BA; Bonhoeffer S; Astill TP; Kost R; Hurley A; Cao Y; Markowitz M; Ho DD; Moore JP
    J Exp Med; 1998 Jul; 188(2):233-45. PubMed ID: 9670036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virus-specific antibody production and polyclonal B-cell activation in the intestinal mucosa of HIV-infected individuals.
    Eriksson K; Kilander A; Hagberg L; Norkrans G; Holmgren J; Czerkinsky C
    AIDS; 1995 Jul; 9(7):695-700. PubMed ID: 7546413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses.
    Notermans DW; de Jong JJ; Goudsmit J; Bakker M; Roos MT; Nijholt L; Cremers J; Hellings JA; Danner SA; de Ronde A
    AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1003-8. PubMed ID: 11485617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus (HIV) type 1 strain MN neutralizing antibody in HIV-infected children: correlation with clinical status and prognostic value.
    Robert-Guroff M; Roilides E; Muldoon R; Venzon D; Husson R; Marshall D; Gallo RC; Pizzo PA
    J Infect Dis; 1993 Mar; 167(3):538-46. PubMed ID: 7680059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.
    Brozy J; Schlaepfer E; Mueller CKS; Rochat MA; Rampini SK; Myburgh R; Raum T; Kufer P; Baeuerle PA; Muenz M; Speck RF
    J Virol; 2018 Jul; 92(14):. PubMed ID: 29720517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of spontaneous HIV-1 specific and non-specific B-cell responses in patients receiving antiretroviral therapy.
    Fournier AM; Baillat V; Alix-Panabieres C; Fondere JM; Merle C; Segondy M; Huguet MF; Reynes J; Vendrell JP
    AIDS; 2002 Sep; 16(13):1755-60. PubMed ID: 12218386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of peripheral HIV-1-specific memory B cells in patients untreated or receiving highly active antiretroviral therapy.
    Fondere JM; Huguet MF; Yssel H; Baillat V; Reynes J; van de Perre P; Vendrell JP
    AIDS; 2003 Nov; 17(16):2323-30. PubMed ID: 14571183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions.
    Llano A; Carrillo J; Mothe B; Ruiz L; Marfil S; García E; Yuste E; Sánchez V; Clotet B; Blanco J; Brander C
    J Transl Med; 2013 Feb; 11():48. PubMed ID: 23433486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of HIV-1 Regulatory and Structural Proteins as Antigen Candidate in Mice and Humans.
    Khojasteh NF; Fekri M; Shabani SH; Milani A; Baesi K; Bolhassani A
    Curr HIV Res; 2021; 19(3):225-237. PubMed ID: 33243125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection.
    De Milito A; Nilsson A; Titanji K; Thorstensson R; Reizenstein E; Narita M; Grutzmeier S; Sönnerborg A; Chiodi F
    Blood; 2004 Mar; 103(6):2180-6. PubMed ID: 14604962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infection.
    Adalid-Peralta L; Godot V; Colin C; Krzysiek R; Tran T; Poignard P; Venet A; Hosmalin A; Lebon P; Rouzioux C; Chene G; Emilie D;
    J Leukoc Biol; 2008 Apr; 83(4):1060-7. PubMed ID: 18182457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design.
    Cagigi A; Nilsson A; De Milito A; Chiodi F
    Vaccine; 2008 Jun; 26(24):3016-25. PubMed ID: 18164520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization of the circulating anti-HIV-1 gp120-specific B cell repertoire using antibody phage display libraries generated from pre-selected HIV-1 gp120 binding PBLs.
    Koefoed K; Farnaes L; Wang M; Svejgaard A; Burton DR; Ditzel HJ
    J Immunol Methods; 2005 Feb; 297(1-2):187-201. PubMed ID: 15777942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point.
    Trkola A; Kuster H; Leemann C; Oxenius A; Fagard C; Furrer H; Battegay M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Bonhoeffer S; Günthard HF;
    Blood; 2004 Sep; 104(6):1784-92. PubMed ID: 15187026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific antibody production by blood B cells is retained in late stage drug-naïve HIV-infected Africans.
    Béniguel L; Bégaud E; Cognasse F; Gabrié P; Mbolidi CD; Marovich MA; Cazorla C; Lucht F; Genin C; Garraud O
    Clin Dev Immunol; 2004 Jun; 11(2):121-7. PubMed ID: 15330447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow plasma cells are a primary source of serum HIV-1-specific antibodies in chronically infected individuals.
    Montezuma-Rusca JM; Moir S; Kardava L; Buckner CM; Louie A; Kim LJ; Santich BH; Wang W; Fankuchen OR; Diaz G; Daub JR; Rosenzweig SD; Chun TW; Li Y; Braylan RC; Calvo KR; Fauci AS
    J Immunol; 2015 Mar; 194(6):2561-8. PubMed ID: 25681347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of Antibodies to Native Trimeric Envelope and Their Fc-Dependent Functions in Untreated and Treated Primary HIV Infection.
    Nagel L; Kant S; Leeks C; Routy JP; Tremblay C; Thomas R; Szabo J; Côté P; Trottier B; LeBlanc R; Rouleau D; Dupuy FP; Bernard NF;
    J Virol; 2021 Nov; 95(24):e0162521. PubMed ID: 34586863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.
    Gottardo R; Bailer RT; Korber BT; Gnanakaran S; Phillips J; Shen X; Tomaras GD; Turk E; Imholte G; Eckler L; Wenschuh H; Zerweck J; Greene K; Gao H; Berman PW; Francis D; Sinangil F; Lee C; Nitayaphan S; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Tartaglia J; Robb ML; Michael NL; Kim JH; Zolla-Pazner S; Haynes BF; Mascola JR; Self S; Gilbert P; Montefiori DC
    PLoS One; 2013; 8(9):e75665. PubMed ID: 24086607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of Circulating Immune Complexes in HIV-Infected Patients with Different Viral Load.
    Korolevskaya LB; Shmagel KV; Shmagel NG
    Bull Exp Biol Med; 2015 Aug; 159(4):469-71. PubMed ID: 26388572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restricted isotype, distinct variable gene usage, and high rate of gp120 specificity of HIV-1 envelope-specific B cells in colostrum compared with those in blood of HIV-1-infected, lactating African women.
    Sacha CR; Vandergrift N; Jeffries TL; McGuire E; Fouda GG; Liebl B; Marshall DJ; Gurley TC; Stiegel L; Whitesides JF; Friedman J; Badiabo A; Foulger A; Yates NL; Tomaras GD; Kepler TB; Liao HX; Haynes BF; Moody MA; Permar SR
    Mucosal Immunol; 2015 Mar; 8(2):316-26. PubMed ID: 25100291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.